Hepatitis C Virus Infection Completed Phase 3 Trials for Pibrentasvir (DB13878)

IndicationStatusPhase
DBCOND0033268 (Hepatitis C Virus Infection)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02939989Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical StudyTreatment
NCT02738138A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)Treatment
NCT02642432A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated CirrhosisTreatment